冠心病血清超敏C-反应蛋白和血清淀粉样蛋白A，脂联素的关系

摘要：目的：探讨冠心病（CHD）患者血清超敏C-反应蛋白（hs-CRP）、血清淀粉样蛋白A（SAA）和血清脂联素（APN）的关系。方法：人选确诊冠心病的患者66例（CHD组）,正常者20例（正常对照组）。分别测定其血清hs—CRP、SAA、APN水平,并进行比较。结果：CHD组hs—CRP、SAA水平分别为（2．88±0．61）mg／L和（9．89±5．23）mg／L,明显高于正常对照组的（0．67±0．17）mg／L和（1．27±1．11）mg／L,P均〈0．01;CHD组APN水平为（3．38±0．26）μg／L,显著低于正常对照组的（3．91±0．34）／Lg／L,P〈0．05。hs—CRP水平与SAA水平呈正相关（r=0．835,P〈0．05）,与APN水平呈负相关（r=-0．285,P〈0．05）。结论：CHD患者血清hs—CRP、血清淀粉样蛋白A水平明显升高,血清脂联素水平明显降低,血清hs—CRP水平与淀粉样蛋白A水平呈正相关,与脂联素水平呈负相关,可作为临床诊断和预后判断的依据。     

急诊PCI术前阿托伐他汀强化治疗对STEMI患者血清炎症因子的影响

目的：探讨术前给予80mg阿托伐他汀强化治疗对ST段抬高急性心肌梗死（STEMI）患者急诊介入治疗前后炎症反应的影响。方法：入选STEMI的患者95例,随机分为三组：A组（31例,术前给予负荷剂量阿托伐他汀80mg,术后给予阿托伐他汀40mg／d）;B组（34例,术前不服用他汀类药物,术后给予阿托伐他汀40mg／d）;c组（30例,术前不服用他汀类药物,术后给予常规剂量阿托伐他汀20mg／d）。分别于术前,术后24h、3d、7d测定各组血清高敏C反应蛋白（hsCRP）、血清淀粉样蛋白酶A（SAA）水平及术后肌酸激酶-同工酶（CK—MB）的峰值。结果：三组间术前血清hsCRP及SAA水平无明显差异;术后3d及7d,A组血清hsCRP及SAA水平明显低于B组、c组[7d：hsCRP（5．64±1．55）mg／L比（8．36±2．32）mg／L、（7．66±2．53）mg／L,SAA（7．31±3．61）mg／L比（10．13±5．13）mg／L、（12．86±4．98）mg／L,P〈0．051;而B组与C组间无显著差异（P〉0．05）。术后A组CK—MB峰值水平明显低于B、C组[（233．9±102．71）IU／L比（319．40±111．10）IU／L、（373．6±174．87）[U／L,P〈0．05],而B组与c组间无显著差异（P〉0．05）。A组在研究期间药物安全性与B、c两组比较亦无显著差异。结论：急诊PCI术前给予80mg阿托伐他汀强化治疗可显著降低ST段抬高急性心肌梗死患者血清炎性因子水平及肌酸激酶一同工酶峰值水平,且安全性良好。     

老年冠心病患者冠状动脉狭窄程度与血清胆红素水平的相关性

目的：探讨老年心血管病患者的冠脉狭窄程度与血清胆红素水平的关系及意义。方法：对264例老年冠心病患者行冠脉造影并测定血清胆红素水平。依据冠脉造影结果,患者被分为正常对照组（68例）和冠心病组（196例）,其中冠心病组又分为轻度组（66例）、中度组（64例）和重度组（66例）。结果：单因素方差分析显示,与正常对照组比较,冠心病轻、中、重组间血清总胆红素[（20.52±6.12）μmol/L比（18.07±5.81）μmol/L比（14.22±5.19）μmol/L比（15.63±6.30）μmol/L]、间接胆红素[（18.80±5.21）μmol/L比（15.46±6.71）μmol/L比（11.63±3.42）μmol/L比（13.37±4.35）μmol/L]水平显著下降（P〈0.05～〈0.01）;多元线性回归分析显示,血清总胆红素及间接胆红素与冠状动脉狭窄程度的评分呈明显负相关（其偏相关系数分别为-8.976、-2.492,P〈0.05）。结论：胆红素水平与老年心血管疾病的发生发展及其严重程度有密切相关,血清总胆红素和间接胆红素水平可作为临床预测冠脉病变严重程度和病变范围的一个良好指标。     

血清淀粉样蛋白A与老年冠心病患者冠状动脉病变严重程度的相关性分析

目的分析血清淀粉样蛋白A(SAA)与老年冠心病患者冠状动脉病变严重程度的相关性。方法选择2014年6月~2015年6月在我院接受住院治疗的168例胸痛患者,其中男性85例,女性83例,年龄60~82(68.21±5.61)岁。所有入选的胸痛患者均行冠状动脉造影术,根据冠状动脉造影的结果分为冠心病组121例和非冠心病(non-CHD)组47例。冠心病组根据其亚型又分为:稳定性心绞痛(SAP)组36例、不稳定性心绞痛(UAP)组48例、急性心肌梗死(AMI)组37例。所有患者根据是否行PCI术分为PCI组100例,non-PCI组68例。采用ELISA法检测SAA水平,Gensini评分评价冠状动脉病变的严重程度。结果冠心病组患者血清SAA水平明显高于nonCHD组患者[(139.20±87.42)mg/L vs(31.69±6.69)mg/L,P=0.005]。AMI组及UAP组的血清SAA水平明显高于SAP组和non-CAD组[(224.11±91.98)mg/L及(135.80±42.82)mg/L vs(56.46±18.98)mg/L和(31.69±6.69)mg/L],且AMI组明显高于UAP组。相关分析显示,血清SAA水平与LDL-C呈负相关(r=-0.081,P=0.040),总体血清SAA水平与Gensini评分呈正相关(r=0.489,P=0.000)。PCI组患者术后7d血清SAA水平较术前明显下降(P0.05)。结论老年冠心病患者血清SAA水平与冠状动脉病变严重程度呈正相关。     

血清 NGAL和Cys-C对老年冠心病患者早期肾损害的诊断价值

目的：探讨老年冠心病患者血清中性粒细胞明胶酶相关脂质运载蛋白（NGAL）和胱抑素 C （Cys-C）水平与心肾功能关系及其对早期肾损害的诊断价值。方法：选择84例老年冠心病患者,NYHA心功能Ⅰ～Ⅳ级（Ⅰ级组30例、II级组28例、Ⅲ～Ⅳ级组26例）,另选择31例老年健康者为健康对照组。测定患者血清 N末端 B型利钠肽原（NT-proBNP）、NGAL和Cys-C等指标,并分析血清 NGAL和 Cys-C水平与 NT-proBNP和估计肾小球滤过率（eGFR）的相关性。应用受试者操作工作特征（ROC）曲线评价血清 NGAL和Cys-C诊断肾功能不全的准确性。结果：健康对照组,NYHAⅠ、II、Ⅲ～Ⅳ级组血清 NGAL [（36.96±21.23）μg/L比（87.80±61.40）μg/L比（141.21±92.96）μg/L比（198.15±98.46）μg/L]和Cys-C [（0.75±0.64）mg/L比（1.40±1.88）mg/L比（2.33±2.03）mg/L比（3.45±1.81）mg/L]水平随着心衰程度加重而升高,以 NYHAⅢ～Ⅳ级组升高最为明显,4组血清 NGAL水平两两比较均有显著性差异（P＜0.01）,而血清 Cys-C水平除在 NYHAI级组与健康对照组比较无显著性差异（P＞0.05）外,其余各组两两比较差异均有统计学意义（P＜0.05或＜0.01）。Pearson相关分析显示血清 NGAL和Cys-C水平与 NT-proBNP均呈正相关（r值分别为0.842和0.718,P均＜0.01）,与 eGFR均呈负相关（r值分别为-0.689和-0.448,P均＜0.01）,且血清NGAL水平与NT-proBNP和eGFR的相关性更密切。血清 NGAL和Cys-C诊断肾功能不全的 ROC曲线下面积分别为0.884和0.744。结论：老年冠心病慢性心力衰竭患者血清 NGAL和Cys-C水平与心肾功能有较好的相关性,是诊断早期肾损害敏感而准确的指标。     

维吾尔族冠心病心力衰竭患者血浆纤维蛋白原与血清尿酸水平的分析

目的：探讨维吾尔族男性冠心病心力衰竭患者血浆纤维蛋白原（Fg）与血清尿酸（UA）浓度的变化。方法：237例维吾尔族男性冠心病患者。按左室射血分数（LVEF）分为LVEF〉50％组（对照组,86例）和心衰组（LVEF≤50％,151例）,心衰组又分为40％〈LVEF≤50％组（70例）,与LVEF≤40％组（81例）,并根据有无糖代谢异常分为网组,比较不同组间Fg与UA含量的变化。结果：LVEF〉50％组Fg含量[（3．33±0．54）g／L]明显低于心衰两组[（3．54±0．58）g／L,（3．70±0．64）g／L,P〈0．05],在心衰两组明差别无显著性（P=0．092）;三组UA浓度随LVEF值降低明显升岛[（324．55±51．65）mmol／L比（358．21±39．72）mmol／L比（375．57±63．13）mmol／L。P〈0．05];与无糖代谢异常组比较,糖代谢异常组Fg[（3．39±0．60）g／L比（3．65±0．58）g／L]、UA[（333．47±53．40）mmol／1．比（372．60±53．95）mmol／L]含量均明显升高（P〈0．01）;偏相关分析表明Fg和UA水平尢撞著相关性（r=0．08,P=0．23）;Fg、UA与LVEF均呈负相关（r=-0．257,-0．41,P均〈0．001）。结论：冠心病患背血浆纤维蛋白原和血清尿酸含量娃著增加,与心力衰竭密切相关,是心功能恶化的预测因子,其中尿酸变化更明显;糖代谢异常患者较糖代谢正常者纤维蛋白原与尿酸含量更明显增加。     

老年高血压患者颈动脉硬化与血清胆红素及C一反应蛋白的关系探讨

目的研究老年高血压患者颈动脉硬化与血清胆红素和C一反应蛋白（CRP）的关系。方法对l98例老年高血压患者进行血清胆红素和c一反应蛋白水平检测,根据超声检测结果将患者分为动脉硬化组和非动脉硬化组。其中动脉硬化组再分为有无斑块两亚组。结果动脉硬化组中血清cRP明显高于非动脉硬化组（4．1mg／L土1．1rag／L比2．3mg／L±0．7mg／LP〈0．05）,而血清总胆红素明显低于非动脉硬化组（12．8／＊mol／L±1．3／Umol／I．比16．8〉mol／L±1．5／Umol／I．,P〈0．05）。校正年龄、总胆固醇、糖尿病和收缩压等危险因素后,颈动脉硬化组患者血清CRP和颈动脉硬化明显正相关,其中男性OR值为1．95（95％CI1．46～2．82,P〈0．01）,女性OR值为1．76（95％CI1．36～2．04,P〈O．05）;而血清胆红素水平和颈动脉硬化呈负相关关系,其中男性（浓为0．66（95％C10．46～0．80,P〈0．01）,女性OR为0．49（95％CIO．28～0．71,P〈0．01）。结论颈动脉硬化与老年高血压患者卒中或心肌梗死发生密切相关。血清C-反应蛋白和颈动脉硬化正相关．而血清胆红素与颈动脉硬化呈负相关关系。     

血清尿酸与脑梗死复发的相关性分析

目的探讨血清尿酸水平与老年脑梗死患者复发的关系。方法以2006年1月1日至2008年12月30Et期间在山东省4家医院住院的老年急性脑梗死患者1033例为研究对象,采用回顾性分析方法,收集人口统计学、生活方式、疾病史、入院尿酸水平以及脑梗死病史。采用多因素分析方法分析尿酸水平与脑梗死复发的关系。结果复发脑梗死患者尿酸水平明显高于初发脑梗死患者,多因素调整后尿酸水平每升高1个单位,脑梗死患者复发的相对危险性比值比（OR）（95％可信区间CI）为1．002（1．000～1．003）,显示尿酸水平升高与脑梗死复发相关联。进一步按尿酸四分位数进行分析,与尿酸最低四分位（〈211lμmol／L）水平的脑梗死患者相比,尿酸水平在263～333μmol／L、≥333μmol／L的患者发生不良结局的OR值（95％CI）分别为1．951（1．340～2．839）、1．670（1．140～2．448）。而在211~263μmol／L水平,这种趋势无统计学意义。结论血清尿酸水平升高是脑梗死复发的独立危险因素。     

超敏C反应蛋白与绝经后女性冠心病发病的相关性研究

目的探讨超敏C反应蛋白（hs—CRP）预测绝经后女性冠心病的价值。方法选择100例绝经后女性患者，分为冠心病组55例，非冠心病组为45例。对比两组患者的超敏C-反应蛋白、血脂及血清雌二醇有无差异，采用SAS统计软件进行处理分析。结果①绝经后女性冠心病组的血清hs～CRP水平明显高于非冠心病组[（5．28±3．95）mg／L比（1．78±1．28）mg／L，P〈0．05]。②冠心病组的血清雌二醇水平低于非冠心病组[（80．46±12．39）pmol／L比（113．62±16．87）pmol／L，P〈0．05]。③绝经后女性冠心病血清hs～CRP水平与血脂及雌二醇之间无相关性。结论血清hs～CRP与绝经后女性冠心病的发病有明显的关系，血清hs—CRP水平升高可作为预测绝经后女性冠心病发生的危险因素。     

老年冠心病与血清炎性因子的关系

目的探讨血清白细胞介素6(interleukin-6,IL-6)、TNF-α和抗炎因子IL-10与老年冠心病的关系。方法选取老年冠心病患者471例作为冠心病组,同期选择冠状动脉造影证实无冠状动脉狭窄的非冠心病患者作为对照组405例,记录患者的临床资料,包括年龄、体质量指数(BMI)、血糖、TC、TG、HDL-C、LDL-C等,同时采用酶联免疫吸附试验检测2组患者的血清IL-6、IL-10、TNF-α等炎性因子水平,并进行分析。结果冠心病组患者LDL-C和TG水平高于对照组,而HDL-C水平低于对照组,差异均有统计学意义(P<0.01)。冠心病组血清IL-6及TNF-α水平明显高于对照组[(136.18±22.76)μg/Lvs(115.96±18.94)μg/L,(134.11±36.56)μg/Lvs(97.99±30.99)μg/L]、冠心病组血清IL-10水平低于对照组[(92.99±39.92)μg/L vs(144.48±65.96)μg/L],差异均有统计学意义(P<0.01)。结论血清IL-6和TNF-α可能与老年患者冠心病的发生相关;血清IL-10可能与冠心病的发生呈负相关。     

Hyperhomocystinemia: a risk factor or a consequence of coronary heart disease?

BACKGROUND: Mild hyperhomocystinemia has been suggested as an indicator of an increased risk of cardiovascular disease. OBJECTIVE: To examine whether serum homocysteine concentration is a predictor of coronary heart disease (CHD) events. METHODS: A case-control study, nested in a population-based cohort study was used. During a follow-up of 13 years, 166 major coronary events (death from CHD or nonfatal myocardial infarction) occurred in men with evidence of heart disease at baseline and 272 events in men without a history of heart disease. Two controls per case were selected by individual matching. RESULTS: Among men with known heart disease at baseline, the relative risk (95% confidence interval) of CHD events adjusted for age, smoking, hypertension, diabetes mellitus, serum cholesterol level, body mass index, and alcohol consumption was 2.23 (95% confidence interval, 1.03-4.85) in the highest serum homocysteine quintile compared with the lowest quintile. Among the men free of heart disease at baseline, the corresponding relative risk was 0.90 (95% confidence interval, 0.51-1.60). CONCLUSIONS: This prospective study does not support the hypothesis that a high concentration of serum homocysteine is a risk factor for coronary events in a population free of heart disease. However, it does suggest that mild hyperhomocystinemia predicts secondary coronary events in men with heart disease, possibly as a consequence of atherosclerotic changes.     

Discriminative value of serum amyloid A and other acute-phase proteins for coronary heart disease

We studied the value of serum amyloid A (SAA), a first-class acute-phase protein, as a marker for coronary heart disease (CHD) in a middle-aged male population. In a working population of 16 307 men (age, 35–59 years), 446 cases had a history of CHD or prominent Q:QS waves on electrocardiogram. For each case, two matched controls were investigated. SAA, measured by immunonephelometry, was correlated with other acute-phase proteins, cardiovascular risk factors, and infectious serology markers. SAA concentrations were significantly higher in the cases than in controls (P<0.05) and correlated with serum C-reactive protein (CRP) (r=0.61), plasma fibrinogen (r=0.39), serum haptoglobin (r=0.26), and body mass index (r=0.13) (P<0.001). Serum CRP is a better marker for CHD than SAA, which showed discriminative power only in a univariate model comparing highest versus lowest tertile (odds ratio, 1.39; 95% confidence interval, 1.03–1.87). Neither SAA nor other acute-phase proteins correlated with Chlamydia pneumoniae immunoglobulin (Ig)G, Helicobacter pylori IgG and IgA, and cytomegalovirus IgG. In conclusion, although SAA has a discriminative value for CHD, serum CRP is to be preferred as a first-class acute-phase reactant for detection of the disease.     

Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) Study

OBJECTIVES: The goal of this study was to assess soluble intercellular adhesion molecule-1 (sICAM-1) level as a predictor of future acute coronary events in patients with chronic coronary heart disease (CHD). BACKGROUND: Increased sICAM-1 concentration has been shown to be associated with the incidence of CHD in healthy persons. Its significance in patients with CHD has been scarcely investigated. METHODS: We designed a prospective, nested case-control study. Sera were collected from patients with CHD enrolled in a secondary prevention trial that evaluated the efficacy of bezafibrate in reducing coronary events. We measured baseline sICAM-1 concentration in the sera of patients who developed subsequent cardiovascular events (cases: n = 136) during follow-up (mean: 6.2 years) and in age- and gender-matched controls (without events: n = 136). RESULTS: Baseline serum concentrations of sICAM-1 were significantly higher in cases versus controls (375 vs. 350 ng/ml; p < 0.05). Each 100 ng/ml increase in sICAM-1 concentration was associated with 1.27 (95% confidence interval [CI]: 1.00 to 1.63) higher relative odds of coronary events. Soluble ICAM-1 concentration in the highest quartile (>394 ng/ml) was associated with significantly higher odds of coronary events (compared with the lowest quartile), even after multivariate adjustment (2.31, 95% CI: 1.02 to 5.50). After adding fibrinogen and total white blood cell count to the multivariate model, the relative odds were 2.12 (95% CI: 0.88 to 5.35) and 2.70 (95% CI: 1.10 to 7.05), respectively. CONCLUSIONS: Elevated sICAM-1 concentration in CHD patients is associated with increased risk of future coronary events independent of other traditional risk factors.     

牙周炎的血清学炎性因子水平与冠心病的关系

目的：通过检测血清炎性因子水平的变化来探讨牙周炎与冠心病（CHD）之间的相互关系。方法：选择我院CHD患者197例作为研究对象,其中CHD＋牙周炎组123例、单纯 CHD组39例、单纯牙周炎组35例,另外选择健康者（45例）为健康对照组。检测各组肿瘤坏死因子-α（TNF-α）、白介素-6（IL-6）、血清淀粉样 A蛋白（SAA）、超敏C反应蛋白（hsCRP）的含量及血浆纤维蛋白原（Fg）含量,比较4组间各炎性因子水平的差异。结果：与健康对照组比较,CHD＋牙周炎组上述炎性因子均显著升高（P均＜0.01）,与 CHD组或牙周炎组比较, CHD＋牙周炎组 hsCRP [（6.52±2.03）mg/L、（4.34±1.76）mg/L比（9.21±2.65）mg/L]、IL-6[（65.32±21.01）ng/L、（65.12±12.34）ng/L比（85.76±25.96）ng/L]、TNF-α[（9.75±3.74）ng/L、（9.34±4.55） ng/L比（13.46±8.12）ng/L],SAA [（2.25±1.2）pg/ml,（2.22±1.02）pg/ml比（2.85±1.45）pg/ml]水平明显升高（P均＜0.05）;CHD组与牙周炎组比较血清炎性因子均无显著差异（P 均＞0.05）。结论：牙周炎的血清炎性因子水平显著升高,与冠心病有一定关系。     

Endothelin-1 and prevalent coronary heart disease in older men and women (the Rancho Bernardo Study)

Endothelin-1 has been implicated in atherosclerotic and ischemic heart disease. No population-based studies have examined the association of endothelin-1 with coronary heart disease (CHD). We performed a cross-sectional analysis of 961 older women and men. CHD was defined as a history of myocardial infarction, coronary surgery, angina, or major Q-wave abnormality on electrocardiography. We examined the association of endothelin-1 with CHD after adjusting for known risk factors and atherosclerosis measures. A total of 248 women and 156 men had CHD. Median endothelin-1 levels were similar by gender and higher among those with versus those without CHD (3.3 vs 3.1 pg/ml, p <0.001). After adjusting for age, smoking, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, hypertension, diabetes, alcohol use, exercise, aspirin, cholesterol-lowering medication, and hormone therapy use, endothelin-1 had a stronger association with CHD in women (odds ratio [OR] 3.02, (95% confidence interval 1.43 to 6.37) than in men (OR 1.82, 95% confidence interval 0.74 to 4.51). Age modified the effect of endothelin-1 with CHD in men (OR 0.47 for age <75 years vs 3.84 in men >or=75 years, p = 0.05 for interaction). Further adjustment for ankle-brachial index and carotid intima media thickness did not alter these results. In conclusion, higher endothelin-1 levels are independently associated with CHD in women of all ages and among older men only.     

冠心病患者血浆淀粉样蛋白A水平的变化

目的分别观察冠心病患者血浆中淀粉样蛋白A(serum amyloid A,SAA)和HDL中SAA水平的变化,探讨SAA与动脉粥样硬化之间的关系。方法应用酶联免疫吸附测定法分别检测冠心病组65例及对照组62例血浆中SAA和HDL中SAA的水平,同时对2组其他心血管危险因素、血脂水平和hs-CRP进行比较。结果冠心病组高血压史、吸烟史、冠心病家族史和hs-CRP水平明显高于对照组(P<0.05),血浆中SAA和HDL中SAA含量明显高于对照组,分别为(15.93±12.04)mg/L vs(10.92±11.04)mg/L,(115.22±70.61)mg/L vs(35.92±25.42)mg/L,差异有统计学意义(P<0.001)。logistic回归分析lghs CRP的OR值3.449,95%CI:1.207～9.854;lgSAA的OR值5.909,95%CI:1.531～22.801。结论冠心病患者SAA水平在血浆和HDL中均明显升高,可能是冠心病发病的重要危险因素。     

Relation of serum osteocalcin level to risk of coronary heart disease in Chinese adults

Osteocalcin, a bone-derived polypeptide, was recently found to have hormonal function associated with metabolic disorders and atherosclerosis. Few studies have examined the association between circulating osteocalcin and coronary heart disease (CHD) risk. The aim of the present study was to investigate whether serum osteocalcin concentration was associated with CHD risk and metabolic profiles in Chinese adults. A total of 461 subjects (243 with CHD and 218 without CHD) who underwent coronary angiography were included. Serum osteocalcin, glucose, lipid profiles, and other biochemical markers were measured. Severity of coronary atherosclerosis was estimated by number of diseased vessels. Results showed that serum osteocalcin levels were significantly lower in the CHD group (12.2 ng/ml, 9.5 to 15.1) than in the non-CHD group (13.6 ng/ml, 10.7 to 18.0, p = 0.001) and were significantly decreased with the increasing of number of diseased vessels (p = 0.005). Serum osteocalcin concentration was inversely correlated with fasting and post load 2 hour plasma glucose and hemoglobin A(1c) (p = 0.044, 0.043, and 0.011, respectively), adjusting for CHD status. Odds ratios (95% confidence intervals) of CHD across increasing quartiles of serum osteocalcin were 0.68 (0.42 to 1.12), 0.59 (0.36 to 0.98), and 0.40 (0.23 to 0.69). The test for trend was significant (p = 0.0007). Adjusting for age, body mass index, and other conventional risk factors for CHD did not appreciably change the results. Spline regression analyses indicated a linear relation between serum osteocalcin level and CHD risk. In conclusion, our data indicate that serum osteocalcin level was associated with decreased risk of CHD and protective metabolic changes in Chinese adults.     

The relationship of fasting serum radioimmune insulin levels to incident coronary heart disease in an insulin-treated diabetic cohort

It is not known whether insulin levels, in the setting of insulin treatment, are an independent risk factor for coronary heart disease (CHD). We studied a cohort of 116 insulin-treated individuals, 65 yr or older, who were followed for 5.6-9 yr. All were free of CHD at baseline. There were 47 incident CHD events. In Cox proportional hazards modeling, with fasting immune-reactive insulin levels as a continuous variable, the hazard ratio for CHD was statistically significant (P < 0.0001). When insulin levels were divided into intervals, those in the third interval [43-150 microU/ml (258-900 pmol/liter)] had an adjusted 30% increased relative risk (95% confidence interval, 0.57, 2.98) compared with those in the first interval [<20 microU/ml (<120 pmol/liter)]. Those in the fourth interval [151-400 microU/ml (906-2400 pmol/liter)] had an adjusted 5.6-fold increased risk (2.3-13.1; P < 0.0001). Approximately 15% of the cohort had such elevated insulin levels. Immune-reactive insulin levels were strongly correlated with specific insulin, proinsulin, and insulin antibody levels. Markedly elevated fasting immune-reactive insulin levels were an independent risk factor for CHD in this study of insulin-treated older adults. These observational findings should be confirmed through larger prospective studies, given their implications for insulin therapy.     

Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT).

Hyperlipidemia is primarily implicated in the progression of coronary heart disease (CHD) and its treatment is essential for patients with a history of CHD. Statins such as simvastatin, the lipid-lowering agents, are well-known for their ability to normalize patient's serum lipid levels. The Japan Lipid Intervention Trial study of simvastatin is the first nationwide investigation of the relationship between serum lipid levels and the development of CHD in Japanese patients with hypercholesterolemia. Of 5,127 patients, exclusively with a history of documented CHD at enrollment, 4,673 were treated with open-labeled simvastatin at an initial dose of 5-10 mg/day and were monitored for 6 years. The risk of coronary events tended to be higher in patients with a serum total cholesterol (TC) > or =240 mg/dl compared with total cholesterol <240 mg/dl. The concentration of low-density lipoprotein cholesterol (LDL-C) positively correlated and that of high-density lipoprotein cholesterol (HDL-C) inversely correlated with the risk of CHD. Each 10 mg/dl decrease in LDL-C and each 10 mg/dl increase in HDL-C concentration reduced the risk of CHD by 8.0% (95% confidence interval 3.8-12.0) and 28.3% (95% CI 13.9-40.3), respectively. A reasonable therapeutic strategy to reduce CHD progression in patients with prior CHD under low-dose statin treatment might be regulating the serum LDL-C concentration to at least <120 mg/dl and HDL-C >40 mg/dl, respectively.     

血清淀粉样蛋白A与冠心病及冠心病危险因素的关系

目的 :探讨血清淀粉样蛋白A (SAA)与冠心病 (CHD)及CHD相关危险因素的关系。方法 :用微粒增强免疫比浊法测定SAA的血浆浓度。结果 :急性冠状动脉综合征 (ACS)亚组和稳定型心绞痛 (SAP)亚组SAA血浆浓度均高于对照组 (P <0 .0 1) ;ACS亚组SAA血浆浓度高于SAP亚组 (P <0 .0 1) ;比较CHD危险因素导致CHD发生的危害性 ,SAA >CHD家族史 >TC >吸烟指数 >高血压史。结论 :CHD患者SAA血浆浓度升高可促进动脉粥样斑块的不稳定性 ,导致ACS的发生